TRAX

First Tracks Biotherapeutics

NASDAQ: TRAX · HEALTHCARE · BIOTECHNOLOGY

$36.44

-4.05% today

Updated 2026-09-11

Market cap

$1.41B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.71

Dividend yield

—

52W range

$11 – $50

Volume

0.8M

Market cap

$1.41B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.71

Dividend yield

—

52W range

$11 – $50

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →251 stocks currently score above 75

Price targets

Analyst target

$69.44

+90.56%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.03x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-31.94M

Key financials

Revenue Net Income Free Cash Flow

Metric	2023	2024	2025	TTM
Revenue	$0.00	$0.00	—	$0.00
Net income	$-106.15M	$-163.71M	$-166.09M	$-33.37M
EPS	—	—	—	$-4.71
Free cash flow	$-93.81M	$-126.16M	$-143.01M	$-31.94M
Profit margin	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TRAX	$1.41B	23	4.3	3.0	5.0	7.3	—	Avoid
LLY	$994.92B	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$640.02B	59	4.7	8.5	2.7	6.0	-88.93%	Buy
ABBV	$454.36B	73	6.7	8.5	4.0	5.0	-69.36%	Strong Buy
MRK	$355.10B	36	4.0	4.5	2.0	5.0	-73.74%	Hold
UNH	$340.27B	62	7.3	5.5	4.7	6.0	-16.10%	Buy

Smart narrative

First Tracks Biotherapeutics trades at $36.44. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.

Frequently asked questions

What is First Tracks Biotherapeutics's stock price?

First Tracks Biotherapeutics (TRAX) trades at $36.44.

Is First Tracks Biotherapeutics overvalued?

First Tracks Biotherapeutics carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of First Tracks Biotherapeutics (TRAX)?

The 12-month analyst consensus target is $69.44, about 90.6% above the current $36.44. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-64.51%

Beta—

50D MA$39.14

200D MA$28.11

Shares out0.04B

Float0.03B

Short ratio—

Avg volume0.8M

Performance

1 week+7.27%

1 month+111.65%

3 months+116.88%

YTD—

1 year—

3 years—

5 years—

Compare

TRAX vs LLY →TRAX vs JNJ →TRAX vs ABBV →Stock screener →